Founding Principles
The discipline rests on four founding principles, established by the inventors and codified in the patent portfolio that anchors the field.
- Principle One
Endogenous regulation precedes pharmacological design.
The body operates an extensive regulatory architecture — gene expression cascades, peptide signaling networks, organ-specific bioregulatory pathways — that has evolved over millions of years to maintain homeostasis. Endogenic pharmacology designs therapeutics that participate in this architecture, not therapeutics that bypass it.
- Principle Two
The regulator is the molecule, not the lock.
Conventional pharmacology often binds receptors as agonists, antagonists, or partial agonists — locking the receptor in a chosen state. Endogenic pharmacology releases regulatory molecules that instruct the cell at the level of gene expression, allowing the cell's own machinery to determine what is needed and at what intensity.
- Principle Three
Short peptides are the privileged mechanism.
The class of short peptide bioregulators — typically 2 to 7 amino acids — has demonstrated across four decades of peer-reviewed research the capacity to translocate to the nucleus, bind specific DNA sequences, and modulate gene expression in a tissue-specific manner. They are endogenous, biodegradable, and act in nanomolar concentrations.
- Principle Four
The discipline is empirical, falsifiable, and disciplined.
Endogenic pharmacology is not vitalistic, not mystical, not speculative. It is a research and clinical program supported by published peer-reviewed literature, cross-species evidence, and patent-protected innovation. Its claims are testable and have been tested. Its therapeutic outputs are subject to the same regulatory pathways as any pharmaceutical preparation.